AAAAAA

   
Results: 1-8 |
Results: 8

Authors: Topol, EJ Califf, RM Van de Werf, F Willerson, JT Booth, J White, H Clayman, M Deckelbaum, L Lincoff, AM Ohman, EM Bates, E Gibler, WB Hochman, J Kleiman, N Grinfeld, L Aylward, P Armstrong, PW Heikkila, J Vahanian, A Steg, G Bode, C Adgy, AAJ Guetta, V Ardissino, D Savonitto, S Bar, F Simoons, M Kontny, F White, H Sadowski, Z Seabra-Gomes, R Dalby, A Betriu, A Swahn, E Wilcox, R Frye, RL Bertrand, ME DeMets, D Fox, KKA Fuster, V Lee, KL McCarthy, C Waller, M Scherer, J van de Kerkhove, A Kukulewicz, L Booth, JE Del Valle, M Hibert, D Brannon, D
Citation: Ej. Topol et al., Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO randomised trial, LANCET, 357(9272), 2001, pp. 1905-1914

Authors: Cho, L Topol, EJ Balog, C Foody, JM Booth, JE Cabot, C Kleiman, NS Tcheng, JE Califf, R Lincoff, MA
Citation: L. Cho et al., Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender - Pooled analysis from EPIC, EPILOG and EPISTENT trials, J AM COL C, 36(2), 2000, pp. 381-386

Authors: Lincoff, AM LeNarz, LA Despotis, GJ Smith, PK Booth, JE Raymond, RE Sapp, SK Cabot, CF Tcheng, JE Califf, RM Effron, MB Topol, EJ
Citation: Am. Lincoff et al., Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials, ANN THORAC, 70(2), 2000, pp. 516-526

Authors: Lincoff, AM Califf, RM Moliterno, DJ Ellis, SG Ducas, J Kramer, JH Kleiman, NS Cohen, EA Booth, JE Sapp, SK Cabot, CF Topol, EJ
Citation: Am. Lincoff et al., Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors, N ENG J MED, 341(5), 1999, pp. 319-327

Authors: Lincoff, AM Tcheng, JE Califf, RM Kereiakes, DJ Kelly, TA Timmis, GC Kleiman, NS Booth, JE Balog, C Cabot, CF Anderson, KM Weisman, HF Topol, EJ
Citation: Am. Lincoff et al., Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial, CIRCULATION, 99(15), 1999, pp. 1951-1958

Authors: Marso, SP Lincoff, AM Ellis, SG Bhatt, DL Tanguay, JF Kleiman, NS Hammoud, T Booth, JE Sapp, SK Topol, EJ
Citation: Sp. Marso et al., Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus - Results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitor for Stenting Trial) diabetic substudy, CIRCULATION, 100(25), 1999, pp. 2477-2484

Authors: Scirica, BM Moliterno, DJ Every, NR Anderson, FV Aguirre, FV Granger, CB Lambrew, CT Rabbani, LE Arnold, A Sapp, SK Booth, JE Ferguson, JJ Cannon, CP
Citation: Bm. Scirica et al., Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry), AM J CARD, 84(10), 1999, pp. 1145-1150

Authors: Scirica, BM Moliterno, DJ Every, NR Anderson, HV Aguirre, FV Granger, CB Lambrew, CT Rabbani, LE Sapp, SK Booth, JE Ferguson, JJ Cannon, CP
Citation: Bm. Scirica et al., Racial differences in the management of unstable angina: Results from the multicenter GUARANTEE registry, AM HEART J, 138(6), 1999, pp. 1065-1072
Risultati: 1-8 |